 Dear Investor, I hung up the phone in disbelief. I had always hoped I would hear this news one day. Prayed I would hear it. But never in my wildest dreams did I imagine it would come from... China. A young company, along with one of the world's largest universities, has created a successful, non-invasive system for the treatment of nature's deadliest disease. This firm is already selling -- and holds all the intellectual copyrights and patents for -- a new high-intensity ultrasound therapy for the treatment of liver, breast, kidney and bone cancer. (And is expected to soon get FDA approval to treat several other forms, as well.) But here's the part that really knocked me over... This new treatment is so non-invasive, it doesn't cause skin burns, hemorrhaging, or even "significant discomfort." It's so painless, in fact, that the treatment doesn't even require anesthesia! It sounds like a pipe dream, I know. But it's not. Over 20,000 patients have already been treated using this cutting-edge technology. Tens of thousands more are awaiting treatment now. And -- with a success rate that tops 80% -- medical researchers around the world are agog. Better still, this new cancer treatment is not only safe, effective and painless, it's also highly cost-effective. Without anesthesia, recovery is much quicker. Hospital stays are shorter. That means patients -- and their insurance companies -- pay much, much less. The health ramifications here are colossal. But then, so are the financial ones. Hundreds, if not thousands, of shareholders are about to hit the jackpot, becoming millionaires... some of them many times over. Bear in mind, this young Chinese company was only recently brought public -- by one of the world's premier investment banks, no less -- and is currently trading on the U.S. market. Investors who get in now stand to get very wealthy. Very quickly. This is simultaneously one of the biggest breakthroughs in medical history and one of the most amazing money-making opportunities I've seen in 26 years as a leading investment analyst. In short, you need to own this stock. Today. Because Wall Street isn't going to be able to keep its "China Secret" quiet much longer. Wall Street Isn't Sharing the Secret With a story this big, you'd naturally expect that the major brokerage firms would have their clients stampeding into the stock. But -- brace yourself -- it's not happening... yet. For example, when I checked with a broker at Merrill Lynch, he shrugged. "We don't cover the stock," he said. I called another broker at Morgan Stanley. "We have no opinion on it." I checked with still another broker at Smith Barney. "Never heard of it," he told me. This just didn't add up. After all, this is a well-respected, publicly traded company already making tens of millions of dollars. Net profits have risen more than four-fold in the last three years alone! And yet the major brokerage houses know nothing? So I decided to bury myself deep in the fine print to discover what was really happening... and I found all the confirmation I needed. Public records show this medical technology company's prospects are so hot even conservative General Electric invested heavily into the stock -- amassing a 15% stake in the company at one point. Jackpot! GE is one of the world's largest and most respected companies. You can bet your bottom dollar GE doesn't invest tens of millions of dollars without doing exceedingly thorough research and due diligence. This was just the sort of confirmation I was looking for. However, I was still only beginning to understand what I'd soon come to recognize as one of the greatest investment opportunities of my lifetime. One with the potential to create hundreds of freshly-minted millionaires... The Sound of Opportunity Knocking My name is Dr. Mark Skousen. For 26 years, I've been the editor of one of the nation's most highly regarded investment letters, Forecasts & Strategies. I've also been an economist with the Central Intelligence Agency, appeared frequently on television and at national investment conferences, and am currently Chairman of Investment U, a twice-weekly investment e-letter. You may have read one of my more than two dozen books on finance and investing. Or perhaps you know someone who attended one of my classes on free-market economics at Columbia University or Rollins College. If so, you may know I've spent nearly three decades writing, speaking and advising individual investors on the shortest, most-direct route to complete financial freedom. In the process, I've made my followers millions of dollars... in individual stocks, junk bonds, closed-end funds, precious metals and dozens of special situations. Today I run a highly-successful trading service that shows ordinary investors how to manage their brokerage accounts like a top-performing hedge fund... where we've locked in profits of as much as 322% in three weeks and 487% in seven weeks. In short, after nearly 30 years in the investment advisory business, my subscribers and I have had more than our fair share of success. Today I'd like to share that success with you. The company I've been describing has an exciting new medical technology totally unlike anything else available on the market today. Buying a few shares of this company -- which owns the patents on this breakthrough technology -- gives you the opportunity to make a great deal of money in the weeks ahead. Personally, I believe it's a "ten-bagger" -- a stock likely to rise ten-fold or more. Why? I'm expecting this company to make a couple of important announcements soon that will drive these shares right into the stratosphere. And when I explain what's at stake here, you'll understand why. That's why I strongly suggest you put some money to work in this stock immediately... today. But before you do, let me explain exactly why this opportunity is so enormous. I believe what this company has done is the medical equivalent of putting a man on the moon. Only, as you'll see, it's much more profitable... The Prognosis for a Cancer Breakthrough Let's start with the bare facts. Over $60 billion is spent on cancer treatment in the U.S. each year. That's right... each year. Cancer is our country's most notorious killer. There is not a family in this nation that has not been touched in some way by this dreaded disease. The American Cancer Society estimates that 1.2 million new cancer cases are diagnosed in America alone each year. And the total number of new cancer cases rises every year. You don't have to be Isaac Newton to recognize that with Baby Boomers moving into their "golden years" -- and therefore increasing their susceptibility to cancer -- this company's future growth is all but assured. And there is well-founded speculation that the company will get FDA approval to treat patients in the U.S. as well. When it does, shareholders can expect to rake in the chips. (The European and Japanese FDAs, by the way, are also expected to approve this technology.) In short, this stock is already locked and loaded -- ready to blast off. Thousands of people have already been successfully treated in China. The medical world is flabbergasted. GE owned 15% of this company at one point... and yet Wall Street knows nothing? This truly is Wall Street's big "China Secret." However, I wanted to make absolutely sure that the potential here was as gigantic as the People's Republic itself. So, out of loyalty to my subscribers, I did what I knew I had to do. I jumped on a plane to Beijing...
How to Profit from My Private Meeting
at the Oriental Plaza As an economist with the CIA and award-winning newsletter editor, I've traveled the world many times. But rarely have I traveled to China with so much anticipation. I knew this part of the world had changed a great deal since my last trip to Asia. Still, I was bowled over by how much. China is easily the world's fastest-growing major economy. While economic growth has averaged more than 9% over the past decade, it's recently hit a blistering 17%. China's huge population, of course, is arguably the greatest natural resource on the planet. The nation is rapidly becoming a nation of 1.3 billion consumers, capitalists and entrepreneurs. "To get rich is glorious!" Deng Xiaoping famously proclaimed. And the Chinese have taken it to heart. China is now, in fact, the world's largest maker of clothing and consumer electronics. And it is swiftly moving up the ladder in car production, computer manufacturing, biotechnology and telecommunications thanks to low-cost, high-tech factories. China now lags only the U.S. as the home of foreign direct investment. Of course, it has also rapidly become the center for new advances in medical technology. And that -- specifically -- was why I was here. I had made an appointment to meet privately with Dr. Zhu, Vice President of Business Development with this hot, new leader in cancer treatment. Dr. Zhu arrived on time at the Grand Hyatt Oriental Plaza for our 9:45 meeting. There he laid out for me exactly what the company is doing, how its technology works and what the company's business prospects are. This is what he shared with me -- and I subsequently confirmed: This medical technology leader was founded in 1999. And it was brought public -- by one of the world's premier investment banks -- only last year. (The fact that it's based in Beijing and has been trading less than a year is one reason the stock is not widely followed.) Years before the company went public, it began developing a new high-frequency technology for cancer treatment in collaboration with Beijing University Medical School. The company owns all the intellectual property rights, along with the related patents. Other companies sell ultrasound gear to fight cancer, it's true. But this company's high-intensity focused ultrasound is different. Its waves raise the temperature of target cells to a range of 140-158 degrees Fahrenheit. That destroys them. And it's a non-invasive device. It doesn't cause skin burns, hemorrhaging or even "significant discomfort," according to the company's SEC filings. In fact, it's so pain-free that no anesthesia is needed during treatment. This, of course, leads to shorter hospital stays and reduced costs. It means insurance companies the world over -- and their patients -- are rooting for this technology to become more widely available. Bear in mind, this technology is not on the drawing board. It exists, right now. Today. Dr. Zhu's company has treated over 20,000 cases in China alone. And the average response rate is 80%. That's not just good. It's astonishing. Especially when you consider that the product has mainly been used to treat late-stage cancer patients. Due to its low-risk profile, however, many believe it will soon become a primary frontline treatment method. When this announcement is made, of course, demand for the technology will hit the ceiling. Along with the stock, in my view. My research shows that any hospital with more than 300 beds will have enough patients to benefit from this system. And there are currently more than 17,000 such hospitals in China alone. Patients Are Already Flocking to China In a recent article entitled "A Cancer Treatment You Can't Get Here," BusinessWeek writes that patients from all over the world are flying to China to receive new treatments with the best success rates at killing tumor cells. As BusinessWeek points out, "China is a logical place to work because more than 2 million Chinese get cancer every year. Clinical trials are inexpensive, at about one-tenth the cost in the U.S. And the regulatory climate is favorable."  Of course, the potential here for a serious payday would be big enough with just the company's cancer business. However, the company also sells advanced in vitro diagnostic systems currently used to test for thyroid disorders, diabetes and reproductive disorders.
Its diagnostic systems have also been successfully used for the detection of severe acute respiratory syndrome, or SARS. In other words, there are several other multi-million dollar sectors where the company can compete, as well as cancer treatment. Having done my research, I'm convinced this is the dawn of a new global technology leader. It's run by a superb management team and by professional scientists. (It also has a nationwide sale and customer service network, providing clients and patients with all the information they need.) In short, I've looked into this company from every angle. And I'm satisfied that this firm -- and its business prospects -- are absolutely top notch. Factor in the additional diseases this company's technology can diagnose -- as well as the potential growth in technology sales outside China -- and you have the makings of a world-class blockbuster. Or, as investment legend Peter Lynch would say, "a ten-bagger." This is especially true since the firm is already developing next generation products that promise to be even more accurate... and more effective. Killing Cancer. . . and Making a Killing Too By now I hope you understand the magnitude of this investment opportunity. And I hope too that you act immediately to add this stock to your portfolio.  It is my conviction that this company's stock is one of the most promising investments of the early 21st century. A stock with the potential to make its shareholders exceedingly wealthy.
That's why I've written a special intelligence report exclusively for my subscribers. It details everything you need to know to take advantage of this timely opportunity. (Including, of course, how to buy this NASDAQ stock through any broker such as TD Ameritrade or E-Trade.) It's called "Wall Street's China Secret EXPOSED -- How to Profit from China's Newest Medical Technology." Best of all, the report is absolutely free when you become a new subscriber to my award-winning investment letter, Forecasts & Strategies. As a subscriber, you'll soon be receiving regular updates on the status of this timely investment, as I've just put it at the top of my Recommended List. And when the day comes to pull the trigger -- to lock in our profits -- I'll fire off an alert to you immediately. No one will hear when to take their gains to the bank before you do.
Of course, as a new subscriber to Forecasts & Strategies, you'll soon be enjoying dozens of other benefits as well. 26 Years of Dead-On Market Calls Long-time subscribers to my newsletter will tell you I have dozens of unique, profitable ideas about how to safely earn double-digit income, how to grow your portfolio handsomely even during down markets, and how to keep the bulk of your money safe from the prying hands of the IRS. As a new subscriber, I'll have the opportunity to discuss all these important topics with you in the near future. You'll soon find that I have a perspective on the economy and the markets you won't find anywhere else.  I'm one of the few financial advisers and newsletter writers with a Ph.D. in Economics -- and the only one with extensive experience in the CIA. That means I've got methods of investigation, contacts in business and sources in government that are unavailable to others.
With 26 years of experience, I've seen bull markets, bear markets and everything in between. The record shows that I've alerted my subscribers to market updrafts and downdrafts time and again... well before they occurred. In fact, I've called virtually every major market move over the last 26 years. Independent sources can verify that: I warned in 1980 that gold and silver were dangerously overheated and the time had come to take profits. Precious metals promptly tanked and subsequently lost nearly 75% of their value. I proclaimed in 1982 that Reagonomics would work and said "a long decade of profits is coming." I issued a "sell everything" recommendation just 41 days before the stock market crash of 1987. Then I told investors to get fully invested again just weeks later... I called the Gulf War of 1990 "a turning point for U.S. stocks." The Dow subsequently began a bull market that didn't end for nearly ten years. I told subscribers in 1995 that the NASDAQ would double... and then double again. Using economic analysis, I recently issued a special report entitled "The Map That Predicted the Terrorist Attacks – What Is It Predicting Now?" In every issue I show you exactly how to use my "Anti-Terrorist Portfolio" to protect your hard-earned capital, even if the unthinkable occurs. (This alone is worth many times the cost of subscribing.)
While my market calls and individual stock picks have been right on the money, many subscribers insist they take my letter for the income recommendations alone! I'll soon be telling you about high-yielding real estate trusts, corporate bonds with double-digit yields, and deeply discounted funds paying fat monthly dividends.
Perhaps you're looking to increase your investment returns with broad diversification and a high degree of safety. In that case, you'll enjoy reading about my commission-free "No-Load Fund Portfolio."  Are you looking for a way to profit from rising oil and gas prices? I currently have six red-hot gold and natural resource recommendations, and "Five Stocks Set to Fly."
Of course, as a new subscriber, your very first investment will likely be my newest China recommendation. But I have many exciting -- and highly profitable -- investment ideas, and I can't wait to share them with you.
In the months ahead, I'll be increasing your investment returns, lowering your risk profile and keeping the bulk of your profits away from the tax man. In the exciting, fun-to-read pages of my newsletter each month, you'll learn exactly what to do.
Between issues, I also offer a free weekly hotline -- via e-mail, web or phone -- so you're always kept abreast of new developments with each of my recommendations... and particularly Wall Street's "China Secret". Special Offer. . . Subscribe Now
for as Little as $99.95 By now, I hope you understand the value of forming an alliance.
With all these benefits, however, you may be thinking a subscription to my newsletter -- along with my special report "Wall Street's China Secret EXPOSED –- How to Profit From China's Newest Medical Technology" -- is prohibitively expensive. (After all, this medical technology stock alone should be worth many thousands of dollars to you.)  Fortunately, I'm currently offering new subscribers a one-year subscription to my newsletter -- along with this special report -- at the special introductory price of just $99.95.
A one-year subscription generally costs $249, even without this report. But I'm making this offer to you because I feel strongly that my investment insights will have a profound and positive impact on your financial future. So you get everything I've mentioned in this letter, 12 monthly issues of my highly-regarded newsletter Forecasts & Strategies, my new special "China Secret" report, daily access to my website at MarkSkousen.com, free weekly hotline updates, and all the special benefits of joining my growing family of subscribers... all for just $99.95. Consider this an important step in building a legacy of enduring wealth for you and your family. For all these reasons, I urge you to activate your subscription -- and receive this special report via e-mail -- immediately. Simply click on the "Subscribe Now" button below or call toll-free at 1-800-211-7661 to activate your subscription.
However you choose to order, please do it now. Your financial future may well depend on it.
Sincerely,
Mark Skousen, Ph.D.
Forecasts & Strategies P.S. This is the most likely ten-bagger I've seen in years... and it's going to move quickly. To get in on the ground floor with my special report and to start your subscription to Forecasts & Strategies immediately, call us today at 1-800-211-7661. | 
